@prefix biolink: <
https://w3id.org/biolink/vocab/
> .
@prefix ns1: <
https://w3id.org/np/o/ntemplate/
> .
@prefix this: <
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk
> .
@prefix sub: <
http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#
> .
@prefix schema: <
https://schema.org/
> .
@prefix np: <
http://www.nanopub.org/nschema#
> .
@prefix dct: <
http://purl.org/dc/terms/
> .
@prefix rdf: <
http://www.w3.org/1999/02/22-rdf-syntax-ns#
> .
@prefix xsd: <
http://www.w3.org/2001/XMLSchema#
> .
@prefix rdfs: <
http://www.w3.org/2000/01/rdf-schema#
> .
@prefix orcid: <
https://orcid.org/
> .
@prefix prov: <
http://www.w3.org/ns/prov#
> .
@prefix npx: <
http://purl.org/nanopub/x/
> .
sub:Head
{
this:
np:hasAssertion
sub:assertion
;
np:hasProvenance
sub:provenance
;
np:hasPublicationInfo
sub:pubinfo
;
a
np:Nanopublication
.
}
sub:assertion
{
<
http://purl.obolibrary.org/obo/DOID_5844
>
biolink:category
biolink:Disease
.
sub:association
rdf:object
<
http://purl.obolibrary.org/obo/DOID_5844
> ;
rdf:predicate
biolink:treats
;
rdf:subject
<
https://identifiers.org/drugbank:DB00934
> ;
a
rdf:Statement
;
rdfs:label
"Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction." ;
biolink:provided_by
<
https://w3id.org/um/NeuroDKG
> ;
biolink:relation
schema:MedicalContraindication
.
<
https://identifiers.org/drugbank:DB00934
>
biolink:category
biolink:Drug
.
}
sub:provenance
{
sub:assertion
prov:wasAttributedTo
orcid:0000-0002-1468-3557
.
}
sub:pubinfo
{
sub:sig
npx:hasAlgorithm
"RSA" ;
npx:hasPublicKey
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
npx:hasSignature
"dhZfRc575bxoQOZR46xb/A1hQM30wLNF885Gm4fvlaKxveGcWkp+GLZY8t9crRv8EWNNVxnevOI2+8hO/puL8insACSBw3USa8YrpMSJlMf44+hIaeP0mpXQ8SfkSeAKfDK1jS3U15hzJaULewrVDSf/m71SP1Dy9j0AE/6gSBs=" ;
npx:hasSignatureTarget
this:
.
this:
dct:created
"2021-08-25T14:13:30.145+02:00"^^
xsd:dateTime
;
dct:creator
orcid:0000-0002-1468-3557
;
ns1:wasCreatedFromProvenanceTemplate
<
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
> ;
ns1:wasCreatedFromPubinfoTemplate
<
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
> ;
ns1:wasCreatedFromTemplate
<
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY
> .
}